医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Chinese Families’ Compulsory Lianhua Qingwen Launched in the Philippines

2020年12月25日 PM12:00
このエントリーをはてなブックマークに追加


 

SHIJIAZHUANG CITY, China

Lianhua Qingwen Capsules, an innovative patent traditional Chinese medicine (TCM), is produced by China’s Yiling Pharmaceutical under the guidance of TCM Collateral Disease Theory.

This medicine has been widely used in the treatment of influenza caused by toxic heat attacking lung, with symptoms of fever, aversion to cold, muscular soreness, nasal obstruction and running nose, cough, headache, dry and sore throat, reddish tongue, yellow tongue coating or greasy tongue coating. It has been listed in the authoritative guidebook Common Drugs for Chinese Families 2019-2020 due to its extensive use scenarios, good efficacy, and wide acceptance by consumers.

The efficacy of Lianhua Qingwen is not bragged, but with adequate scientific evidence. Yiling Pharmaceutical has taken a lead in the Evidence-based Medicine research in China. The Evidence-based Medicine refers to the use of large-scale, multi-sample, randomized, double-blind clinical trial to test the efficacy of drugs, which is currently the most scientific and impartial drug efficacy evaluation approach. Up to now several Evidence-based Medicine clinical trials have accumulated plenty of proof for its efficacy.

The Philippine Food and Drug Administration has issued approval document for Lianhua Qingwen, and it has been officially launched on November 23. The registration number is THPR-50 and the product category is traditional herbal drugs. The Philippine consumers can now buy it in Mercury Drug, Southstar Drug and Watson since then, and its price is only 288 pesos per pack.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201224005059/en/

CONTACT

First name: Li

Last Name: Kristy

E-mail:kristyli@chuhaimedia.com.cn

Phone No.: +86 85962566

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 企業と政治のリーダーがバイデン大統領宛の書簡に署名し、米国のリーダーシップで世界的なワクチン接種への取り組みを加速させるよう要請
  • 美国政商领袖签署致拜登总统公开信,呼吁美国展现领导力以加速全球疫苗接种工作
  • Ferring和Rebiotix将在2021消化疾病周大会上公布基于微生物群的在研活体生物治疗药物RBX2660的里程碑数据
  • アスターDMヘルスケア、25万米ドル相当の世界看護賞を発表
  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea